Olema Pharmaceuticals, Inc. 8-K

What Happened
Olema Pharmaceuticals (OLMA) announced on January 30, 2026 that Shane Kovacs, the company's Chief Operating and Financial Officer, is leaving to pursue other opportunities effective that day. Mr. Kovacs will continue working as a consultant to the company through August 1, 2026, and the company has begun a search for a successor CFO. The departure is not the result of any disagreement with the company. CEO Sean Bohen, M.D., Ph.D., has assumed the role of principal financial officer on an interim basis as of the separation date.

Key Details

• Separation date: January 30, 2026; consulting period continues through August 1, 2026.
• One-time lump-sum payment to Mr. Kovacs: $621,283 total, consisting of: $562,640 (12 months base salary), $23,443 (prorated 2026 target bonus at assumed 100% achievement), and $35,200 (grossed-up amount intended to cover COBRA health premiums).
• Outstanding equity awards will continue to vest during the consulting period in accordance with their terms.
• CEO Sean Bohen is serving as interim principal financial officer until a permanent successor is appointed.

Why It Matters
For investors, this is a leadership transition at the finance function that may affect near-term financial operations and reporting continuity. The company has committed a one-time cash obligation of $621,283 related to the separation and will rely on the CEO in the interim while searching for a new CFO. Monitor future disclosures for the appointment of a permanent CFO and any related impacts on financial controls, guidance, or operating plans.